A multicentre, single-arm, open-label, first-in-humans phase I trial was carried out in 33 patients with newly diagnosed WHO grade 3 and 4 IDH1 (R132H)+ astrocytomas (NCT02454634). Here, IDH1 is linked to astrocytoma (excluding glioblastoma).